Bezuclastinib

Bezuclastinib

Clinical data
Other names	CGT-9486, PLX-9486
Legal status
Legal status	Investigational
Identifiers
IUPAC name 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide
CAS Number	1616385-51-3
PubChem CID	75593308
IUPHAR/BPS	11868
DrugBank	DB18041
ChemSpider	115007996
UNII	2ROQ545LAG
KEGG	D12600
ChEMBL	ChEMBL5095229
PDB ligand	WEJ (PDBe, RCSB PDB)
Chemical and physical data
Formula	C19H17N5O
Molar mass	331.379 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(NN=C1C(=O)NC2=CN=C3C(=C2)C=C(N3)C4=CC=CC=C4)C
InChI InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24) Key:NVSHVYGIYPBTEZ-UHFFFAOYSA-N

Bezuclastinib is an investigational new drug that is being evaluated for the treatment of solid tumors and systemic mastocytosis. It acts as an inhibitor of KIT (a specific type of receptor tyrosine kinase).